A5041323342- Sarcoma Diagnosis and Treatment
- Gastrointestinal Tumor Research and Treatment
- Gastric Cancer Management and Outcomes
- Soft tissue tumor case studies
- Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Cardiac tumors and thrombi
- Gastrointestinal disorders and treatments
- Vascular Tumors and Angiosarcomas
- Soft tissue tumors and treatment
- Lymphoma Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Metastasis and carcinoma case studies
- Tumors and Oncological Cases
- Peptidase Inhibition and Analysis
- Neurofibromatosis and Schwannoma Cases
- Platelet Disorders and Treatments
- Uterine Myomas and Treatments
- CAR-T cell therapy research
- Renal cell carcinoma treatment
- Bone Tumor Diagnosis and Treatments
- PI3K/AKT/mTOR signaling in cancer
- Radiomics and Machine Learning in Medical Imaging
- Immunotherapy and Immune Responses
- Pediatric Urology and Nephrology Studies
University of Miami
2019-2025
Sylvester Comprehensive Cancer Center
2019-2025
University of Miami Health System
2020-2024
Jackson Memorial Hospital
1998-2022
Emory University
2020-2021
Northside Hospital
2018-2019
Georgia Cancer Specialists
2016-2019
South Texas Accelerated Research Therapeutics
2011
Sarcoma Oncology Center
2011
Moffitt Cancer Center
2003-2010
Purpose Ridaforolimus is an inhibitor of mammalian target rapamycin, integral component the phosphatidyl 3-kinase/AKT signaling pathway, with early evidence activity in sarcomas. This multicenter, open-label, single-arm, phase II trial was conducted to assess antitumor ridaforolimus patients distinct subtypes advanced Patients and Methods metastatic or unresectable soft tissue bone sarcomas received 12.5 mg administered as a 30-minute intravenous infusion once daily for 5 days every 2 weeks....
Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue without approved treatments. Download a PDF of the Research Summary. We conducted phase 3, international, double-blind, randomized, placebo-controlled trial nirogacestat in adults with progressing desmoid according to Response Evaluation Criteria Solid Tumors, version 1.1. Patients were assigned 1:1 ratio receive oral γ-secretase inhibitor (150 mg) or placebo twice daily. The primary end point was progression-free...
Abstract Background Sunitinib inhibits KIT and other members of the split‐kinase‐domain family receptor tyrosine kinases. prolongs survival in adult patients with imatinib‐resistant gastrointestinal stromal tumor (GIST). We report experience sunitinib pediatric advanced GIST following failure imatinib. Procedure therapy was provided through a treatment‐use protocol. Patients were 10–17 years old at enrollment. All had resistant to imatinib therapy. administered daily for 4 weeks 6‐week...
BACKGROUND Alveolar soft part sarcoma (ASPS), chondrosarcoma (CS), chordoma, epithelioid sarcoma, and solitary fibrous tumor (SFT) are malignant tumors that relatively resistant to chemotherapy for which more effective drug therapy is needed. METHODS The 5 listed subtypes were enrolled into a single indolent cohort in phase 2 study of dasatinib using Bayesian continuous monitoring rule enrollment. primary objective was estimate the 6‐month progression‐free survival (PFS) rate according Choi...
Soft tissue sarcomas (STS) represent a diverse group of histologic subtypes with targetable molecular alterations, often treated as single disease. Sunitinib malate is multitargeted receptor tyrosine kinase inhibitor active in other solid tumors carrying similar alterations (i.e., imatinib mesylate-refractory gastrointestinal stromal tumors). This single-institution phase II study investigated the safety and efficacy sunitinib three common STS subtypes. Patients documented unresectable or...
Background We performed a randomized phase 3 study of trabectedin versus dacarbazine in previously‐treated patients with liposarcoma/leiomyosarcoma (LPS/LMS). Methods Patients were 2:1 to (n = 384) or 193) administered intravenously every weeks. The primary objective was overall survival (OS). Secondary objectives progression‐free survival, response rate, safety, and patient‐reported outcomes, all previously reported demonstrating superior disease control trabectedin. Results the final OS...
We performed a retrospective analysis of angiosarcoma (AS) genomic biomarkers and their associations with the site origin in cohort 143 cases. Primary sites were head neck (31%), breast (22%), extremity (11%), viscera (20%), skin at other locations (8%), unknown (9%). All cases had Next Generation Sequencing (NGS) data 592 gene panel, 53 Whole Exome (WES) data, which we used to study microenvironment phenotype. The immunotherapy (IO) response Tumor Mutation Burden (TMB), Microsatellite...
Abstract Purpose: Comprehensive molecular profiling was used to define the genomic and immune landscapes of leiomyosarcomas (LMS) by anatomic subtype, which have not been completely characterized. Design: 1115 LMS samples, categorized into uterine (uLMS), retroperitoneal (rpLMS), or other (oLMS), underwent DNA/RNA sequencing (Caris Life Sciences). Genomic/transcriptomic profiles were compared across subtypes. Immune melanoma (n=1255), an immunogenic tumor. Insurance claims data infer...
Abstract Purpose: Most patients with gastrointestinal stromal tumor (GIST) have activating mutations in KIT/PDGFRA and are initially responsive to tyrosine kinase inhibitors (TKI). The acquisition of secondary leads refractory/relapsed disease. This study reports the results an analysis from phase III INVICTUS (NCT03353753) characterizing genomic heterogeneity tumors advanced GIST evaluating ripretinib efficacy across mutation subgroups. Patients Methods: Tumor tissue liquid biopsy samples...
This was the first phase 1 study conducted in United States. It consisted of dose-escalation (part A) and multiple indication-specific cohort expansion B), investigating safety preliminary efficacy toripalimab (anti-programmed cell death-1 inhibitor) patients with advanced malignancies. Patients malignancies that progressed after treatment at least one prior line standard systemic therapy, including advanced/recurrent cholangiocarcinoma (CCA), received 240 mg every 3 weeks part B. The...
Abstract Objectives Abdominal wall and intra-abdominal fibromatoses are locally aggressive, nonmetastasizing neoplasms. Surgery has been the mainstay of local control, but new forms therapy have developed that may influence clinical course morbidity. We studied features outcomes patients with abdominal over time. Methods Ninety-one patients—46 45 fibromatosis—treated in our hospital systems between 2009 2023 were included. The allocated to 1 2 groups based on year their initial treatment:...
9505 Background: AP23573 is an mTOR inhibitor that has shown anti-tumor activity in phase 1 clinical trials, particularly patients with advanced sarcomas. Given this observation, 2 trial was undertaken to assess further the efficacy and safety of across various sarcoma subtypes. Methods: Advanced pts, no restrictions on prior therapies, were enrolled into 4 cohorts based histologic subtype, a Simon’s 2-stage design. (12.5 mg, i.v.) administered for 5 days every wks. Efficacy assessed using...
10076 Background: AP23573 is an mTOR inhibitor that has demonstrated single-agent activity in a broad range of sarcoma tumor types phase I II trials. Overall survival (OS) was monitored to characterize OS the treated population and subset patients who achieved clinical benefit response (CBR). Methods: Pts with advanced sarcomas, no restrictions on prior therapies, were enrolled into 4 cohorts based histologic subtype, 2, Simon's 2-stage trial. (12.5 mg, i.v.) administered daily × 5 every 2...
Soft tissue sarcomas are the most frequent sarcomas; annual incidence for 2007 in United States is estimated at about 9220 cases, with an overall mortality rate of approximately 3560 cases per year. Important updates version guidelines include addition epirubicin (single agent) and combination epirubicin, ifosfamide, mesna as generally accepted systemic therapy. Imatinib was added option desmoid tumors. For recent guidelines, please visit NCCN.org
Abstract Background Ripretinib 150 mg once daily (QD) is indicated for advanced gastrointestinal stromal tumors (GISTs) as at least fourth-line therapy. In INVICTUS, ripretinib intrapatient dose escalation (IPDE) to b.i.d. was allowed after progressive disease (PD) on QD by blinded independent central review using modified RECIST 1.1. We report the efficacy and safety of IPDE PD among patients randomized in INVICTUS study. Materials Methods Tumor imaging performed every 28-day cycle first...
<h3>Importance</h3> Gastrointestinal stromal tumors (GISTs) are life-threatening when metastatic or not amenable to surgical removal. In a few patients with advanced GISTs refractory imatinib mesylate, treatment sunitinib malate followed by regorafenib provides tumor control; however, additional active treatments needed for most patients. <h3>Objective</h3> To evaluate the 6-month progression-free survival (PFS), objective response, and overall rates in treated dasatinib. <h3>Design,...